Viridian Therapeutics focuses on precision-driven biological research targeting rare and complex autoimmune conditions.

Topline final safety and efficacy results for the full 36 weeks of treatment from all participants will be available in ...

Latozinemab failure, with Nivisnebart Phase 2 data as the next key catalyst. Click here to read more about ALEC stock.

Curious about the animals most often used in research? Get to know the top five—like mice, rabbits, and goats—and the roles ...

UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in ...

Troy’s gut instinct told him: don’t give in—get busy. He began working closely on treatment with his oncologist, as well as ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

The U.S. has registered over half a million clinical trials since 2000. Here's a look at the business and ethics of human ...

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology ...

A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...